Svenska
Boston
An independent LDT provider
Home
About us
Home
About us
Learn more
Vision and mission
Leadership
About us
Leadership
Learn more
Board of directors
Management team
Medical Advisory Board
Collaborations
About us
Collaborations
Learn more
Patient Advocacy Support
Immunovia, Inc.
Immunovia Dx Laboratory, Lund
Company history
Sustainability
About us
Sustainability
Learn more
Sustainability report
Code of conduct
Work environment
Diversity
Calendar
Careers
IMMray™ Platform
Home
IMMray™ Platform
Learn more
Technology
Production
Pancreatic Cancer
IMMray™ Platform
Pancreatic Cancer
Learn more
Pancreatic cancer high risk groups
Clinical performance
Clinical prospective study program
Current technologies for detection and diagnosis
Investors
Media
Home
Media
Learn more
Press releases
Presentations
Webinars
Tutorials
Videos
Audio
Publications
Social media
Media resources
Partnering
Contact Us
Subscribe
Immunovia Inc
English
Svenska
NOTE:
Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:
https://rb.gy/09bxx
Press releases
Type
All types
Regulatory
Non regulatory
Year
All years
2023
2022
2021
2020
2019
2018
2017
2016
2015
February 10, 2016
| REGULATORY
Immunovia and Lund University start clinical validation studies of Systemic Lupus Erythematosus (SLE) biomarker signatures
Read press release
February 9, 2016
| REGULATORY
Immunovia announces collaboration with Mount Sinai Health System to validate early detection blood test for pancreatic cancer
Read press release
January 19, 2016
| REGULATORY
Immunovia and the University of Liverpool enter into a collaboration in a prospective clinical study
Read press release
December 18, 2015
| REGULATORY
White Paper outlines predicted impact of new biomarker diagnostic technology on pancreatic cancer survival rates
Read press release
December 3, 2015
| REGULATORY
IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective study with 1400 blood samples
Read press release
December 2, 2015
| REGULATORY
Immunovia’s stock increased 60 percent on first day of trading on Nasdaq First North with a turnover of SEK 28.5 million
Read press release
November 26, 2015
Immunovia approved for trading on Nasdaq First North as of December 1st, 2015
Read press release
October 5, 2015
Immunovia, OHSU collaborating on early detection test for pancreatic cancer
Read press release
<
1
…
24
25
26
Home
Press releases
Page 26